Back to Guavy Wire

Stocks

Amgen Inc (AMGN) Shares Surge on Strong Performance, but Overvaluation Raises Concerns

Guavy AI Editorial Team Published September 30, 2026

Instruments

AMGN

Amgen Inc (AMGN) shares rose by 1.3% to $423.64 on September 29, 2026, within a 52-week range of $274.02 to $447.03.

This price movement reflects strong year-to-date and past-year performances of +32.1% and +58.9%, respectively.

The GF Value estimate is $367.64, indicating that the stock is 15.2% overvalued compared to its intrinsic value.

The company's financial strength score is 4/10, with concerns regarding its balance sheet influencing long-term stability.

More on Stocks

Stocks just now

Coca-Cola Scores Big with FIFA Campaign and Patriotic Push

Stocks 2m ago

Boeing Secures $20 Billion Contract for Navy's Sixth-Generation Fighter

Stocks 2m ago

GS Credit Redemption Requests Slow to 2% Amid Easing Industry Pressure

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy